Xcout Intel
SAB Biotherapeutics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to SAB Biotherapeutics, Inc. among biotech companies — ranked by similarity to what SAB Biotherapeutics, Inc. actually does, not by market-cap band.
Subscribe to see SAB Biotherapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
SAB Biotherapeutics, Inc. at a glance
SAB Biotherapeutics, Inc. is a biotech company headquartered in Miami Beach, United States. It is publicly listed (SABS) with a market capitalisation of $343.9M. Xcout tracks 31 named people at SAB Biotherapeutics, Inc., including Samuel J. Reich (CEO & Director). Xcout recorded 1 job posting from SAB Biotherapeutics, Inc. in the last 90 days.
SAB Biotherapeutics, Inc. leadership
- Samuel J. ReichCEO & Director
- Christoph BauschExecutive Vice President & Chief Operating Officer
- Lucy ToExecutive Vice President & Chief Financial Officer
- Alexandra KropotovaExecutive Vice President & Chief Medical Officer
- Eddie Joe SullivanCo-Founder, President & Director
- Angie ParizekSenior Vice President of Clinical Operations
25 more named people on record for SAB Biotherapeutics, Inc., with roles, board committees and tenure — see the full roster →
SAB Biotherapeutics, Inc. funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $14M | 2 named |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at SAB Biotherapeutics, Inc.
Xcout recorded 1 job posting from SAB Biotherapeutics, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see SAB Biotherapeutics, Inc.'s hiring signals →
Top 12 SAB Biotherapeutics, Inc. competitors
Ranked by semantic similarity — how close each company is to SAB Biotherapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Biotechnology
Polyneuron Pharmaceuticals is a venture-backed biotech and life sciences company headquartered in Basel, Switzerland. Founded in 2014, the company is pioneering a novel therapeutic approach for the effective and safe treatment of antibody-mediated autoimmune diseases.
Biotechnology
Paulex Bio Inc. is a biotechnology company headquartered in San Diego, California, focused on transformative treatments for type 1 and type 2 diabetes. Its lead approach targets beta cell regeneration through an oral administration.
Similar biotech company
Cyxone AB is a clinical-stage biotechnology company headquartered in Malmö, Sweden. It focuses on developing a new generation of disease-modifying therapies for autoimmune and autoinflammatory diseases.
Similar biotech company
Tr1X is a private, clinical-stage biotechnology company focused on developing regulatory T cell-based products for autoimmune and inflammatory diseases. The company aims to advance Tr1-based immunotherapies to address unmet medical needs and is headquartered in San Diego, California.
Biotechnology
Zag Bio is a biotechnology research company headquartered in Cambridge, Massachusetts. The enterprise focuses on developing innovative therapies for autoimmune diseases by targeting the thymus gland to engage the body's natural T cell central tolerance mechanisms.
Biotechnology
IgGenix is a clinical-stage, venture-backed biotechnology company founded in 2019 and headquartered in South San Francisco, California. The company leverages its proprietary antibody discovery platform with a primary mission to cure allergies and other immunological diseases.
Biotechnology
Soteria Biotherapeutics, Inc. is a biopharmaceutical company founded in 2018 and headquartered in San Francisco, California, specializing in biopharmaceutical advancements and drug pipelines.
Similar biotech company
XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad spectrum of medical conditions such as cancer, stroke, heart attack, and arthritis. Interleukin-1 alpha itself plays a crucial role in biological processes like tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and inflammation. Additionally, XBiotech is developing a True Human COVID-19 therapy specifically targeting mutant strains of the virus. Established in 2005, XBiotech Inc. maintains its headquarters in Austin, Texas.
Similar biotech company
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Biotechnology
Tizona Therapeutics, Inc. is a privately held immunology company founded in 2015 and headquartered in South San Francisco, California. The company focuses on harnessing the power of the immune system to develop treatments.
Biotechnology
AbbraTech Holdings LLC operates a platform technology focused on recombinant antibody discovery, engineering, and validation. The company targets human diseases such as cancer, immune disorders, and viral infections by developing antibodies for difficult-to-reach drug targets through its proprietary Epivolve technology.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of SAB Biotherapeutics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for SAB Biotherapeutics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →